Stocktoria
Sunshine Biopharma Inc. SBFM
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2008-08-15
Sunshine Biopharma Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $36.3M | $34.9M | $24.1M | $4.3M | $228,426 |
| Gross profit | $12.3M | $10.7M | $8.3M | $1.7M | $110,596 |
| R&D expense | $604,308 | $933,902 | $1.9M | $811,858 | $672,209 |
| Operating income | -$6.2M | -$5.8M | -$4.8M | -$27.0M | -$2.4M |
| Interest expense | — | — | $137,308 | $39,412 | $328,818 |
| Income tax | $21,609 | -$234,858 | $395,166 | $233,304 | $0 |
| Net income | -$6.0M | -$5.1M | -$4.5M | -$26.7M | -$12.4M |
| EPS (diluted) | — | $-7.32 | $-351.36 | $-1.76 | $-4.76 |
| Operating cash flow | -$5.3M | -$12.5M | -$8.8M | -$5.2M | -$1.8M |
| Free cash flow | -$5.5M | -$14.2M | -$8.9M | -$5.4M | -$1.8M |
| Cash & equivalents | — | — | — | $21.8M | $2.0M |
| Inventory | $13.5M | $11.3M | $5.7M | $3.3M | $105,650 |
| Total assets | $30.1M | $30.6M | $27.3M | $29.2M | $2.2M |
| Total liabilities | $7.0M | $7.1M | $6.1M | $7.6M | $2.0M |
| Shareholders' equity | $23.0M | $23.5M | $21.2M | $21.6M | $211,662 |
Source: SEC EDGAR filings · CIK 0001402328 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.